



Mpox Clade I:

Many Providers Don't Know What They Don't Know


Survey of 100 U.S. Healthcare Providers, March 5-8, 2024

Methods


Online Survey March 5-8, 2024

- 10-item online Porter Novelli survey
- Sample of 100 healthcare providers from across the United States
- Screened to only include those who said at least 25% of their male patients are gay, bisexual, or men who have sex with men
- Screened to identify provider type, specialty, and practice setting


Most Providers Were MDs/DOs



Most Specialized in Infectious Diseases, Family Medicine, or Internal Medicine



Most Worked in Clinic/Outpatient Setting



Providers Asked About


- Understanding of the differences between mpox clades I and II
- Understanding of when to suspect mpox clade I in patients
- Familiarity with CDC's vaccination recommendations for mpox
- Awareness of where the current clade I outbreak is
- Confidence and comfort in diagnosing, treating, managing mpox clade I
- Biggest challenges diagnosing and managing potential clade I cases
- Information they need to help them better manage patients with clade I

Key Findings


Understanding of Mpox Clades

- **More than 60%** of providers said that they
 - Understand **how both clades of mpox are spread**
 - Are confident they **can identify the symptoms of both clades**
 - Are confident they **know how severe both clades of mpox are**
 - Understand **how to get therapeutics for both clades**
 - Understand the **similarities and differences in both clades**
- However, not all gave accurate responses to knowledge questions.

Knowing When To Suspect Mpox Clade I



Knowing Mpox Vaccination Recommendations



Awareness Where Current Clade I Outbreak Is

- **67%** of providers aware of where the current outbreak of mpox clade I is.
- However, not all gave accurate responses to knowledge questions:
 - **50%** said there **are US cases of clade I**
 - **27%** said they were **not sure** if there are US cases of clade I
 - **23%** said there are **no cases** of clade I in the US

Comfort Diagnosing, Treating, and Managing Cases

- **72%** comfortable **diagnosing** a patient with possible case of mpox clade I.
- **60%** comfortable **treating** a patient with a possible case of mpox clade I.
- **60%** comfortable **managing** a patient with a possible case of mpox clade I.

Comfort Knowing What To Do If They Suspect Clade I

- **78%** comfortable **knowing how to notify appropriate public health officials** about a patient with possible case of mpox clade I.
- When asked what they would do if they suspected mpox clade I:
 - **90%** said they would **consult public health authorities**.
 - **60%** said they would **notify close contacts** of the patient.
 - **34%** said they would **administer vaccine** to the patient.
 - **12%** said they would **notify Poison Control**.

Biggest Challenges in Diagnosing and Managing Potential Mpox Clade I Cases in Your Practice?

- **20% – Lack of familiarity and knowledge:**
 - *“Familiarity of this medical condition; lab testing for this medical condition; symptoms related to this medical condition”*
 - *“Knowing how to diagnose the disease and controlling it once it is diagnosed”*
 - *“Lack of public health knowledge; patients are not seeking care when they need it. Providers are unaware of vaccine recommendations”*

Biggest Challenges in Diagnosing and Managing Potential Mpox Clade I Cases in Your Practice?

- **10% – Confusion over symptoms:**
 - *“Symptoms of mpox clade I infections can mimic those of other illnesses such as influenza or common colds, making it difficult to differentiate without proper testing”*
 - *“It's similarities to other rashes and limited patient history”*


Biggest Challenges in Diagnosing and Managing Potential Mpox Clade I Cases in Your Practice?

- **9% – Treatment access:**
 - *“Lack of Tpoxx availability”*
 - *“Obtaining tecoviromat. Right now, it is through the STOMP study”*
 - *“Testing and getting treatment”*
 - *“Potentially getting swab sent and tested appropriately, access to antivirals as needed”*


Biggest Challenges in Diagnosing and Managing Potential Mpox Clade I Cases in Your Practice?

- **4% – Impact of social stigma:**
 - *“Social stigma and patient unwillingness to bring up the symptoms”*
 - *“Stigma against gay population unfortunately”*
 - *“Stigma against population”*

Most Requested Resources on Mpox



High Interest in Information on Mpox Vaccine



Insights

High Confidence, Limited Knowledge, Clear Need for Clinical Guidance on Mpox Clade I

- Two-thirds expressed confidence in their knowledge of mpox clades.
- Their inaccurate responses to knowledge questions indicate they don't know all they think they know about mpox.
- Challenges include not being familiar with how to manage and treat, confusion over symptoms, concern about impact of stigma.
- They expressed strong need for information:
 - Two-thirds wanted clinical management guidelines.
 - Over half wanted information on diagnostic tests

Limitations

- Respondents were selected from among those who have volunteered to participate in online reach.
- All samples may be subject to multiple sources of error, such as sampling error, coverage error, and error associated with nonresponse or question wording.
- Given the small sample size, results may not be generalizable.

How We Are Using This Feedback

Addressing Knowledge Gaps

- Update Webpages
- Create Content
- Dissemination
- Partner Engagement

Updating Webpages

- Update webpages to include detail about clade I
 - Updating around 116 webpages to ensure Clade I information is included
 - Divided into three phases
 - High
 - Medium
 - Low priority
 - 19 high priority webpages are either **completed** or **in progress**



Specific Updates and Content

- Updating the web and promoting content to address
 - **Confusion about symptoms** recognition
 - Issues related to **testing** and **treatment** access
 - Lack of patient disclosure due to **stigma**
 - Differences between the **two clades**
 - Confusion about **where the clade I outbreak** is
 - Lack of knowledge about **existing clinical guidelines**

Dissemination

- Engage Healthcare Providers through
 - Digital Engagement
 - Doximity
 - Sermo
 - Medscape
 - CDC social media channels
 - COCA Call with Continuing Education
 - Emailing health departments
 - Dear Colleague Letters
 - Presentations



Engaging Partners

- Engage community-based organizations
 - Engage LGBTQ+ organizations at the national and local level
- Engage with medical associations
 - IDSA
 - AMA
 - GLMA
- Cross-center implementation

